TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07837973: Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

Sponsor: Alveus Therapeutics, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 220 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,357,200

Rescue Site Savings

+$1,560,400

Unlock Full NCT07837973 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07837973 Rescue Dossier →